Sponsors (2)
The bill substantially increases federal investments, program scope, and workforce and medication‑access reforms to prevent overdoses and expand treatment, but it raises fiscal costs, administrative burdens, privacy and legal uncertainties, and implementation risks that must be managed to realize intended benefits.
States, Territories, Tribes, and local overdose-response systems receive a large, dedicated infusion of funding (~$505.6M per year FY2026–2030) to expand overdose prevention, harm reduction, and response services.
Programs can address a wider range of drug threats because statutory language is broadened from 'opioids' to 'substances causing overdose,' enabling responses to stimulants, xylazine, synthetic opioids, and other emerging risks.
Pregnant and postpartum people and infants gain sustained and expanded treatment supports through guaranteed CDC prenatal/postnatal funding and increased residential treatment dollars, improving maternal/infant outcomes and access to specialized care.
Taxpayers and the federal budget face materially higher spending from multiple new or increased authorizations (including the large overdose‑prevention allocation), which could require offsets or crowd out other priorities.
HHS, state agencies, grantees, and community providers will face substantial new reporting, evaluation, application, and sustainment requirements that could divert staff time and funds from direct services and disproportionately burden smaller organizations.
Authorized surveillance techniques (for example, wastewater monitoring) raise privacy and civil‑liberties concerns for communities and could erode trust in public‑health programs if safeguards and limits are not robust and transparent.
Based on analysis of 8 sections of legislative text.
Reauthorizes and raises funding for federal substance use prevention, treatment, and recovery programs (FY2026–2030), expands overdose surveillance and scope beyond opioids, and amends controlled‑substance delivery rules for practitioner administration.
Reauthorizes and expands multiple federal substance use prevention, treatment, and recovery programs through FY2026–FY2030, increases authorized funding levels for several grant programs, broadens the scope of overdose prevention activities beyond opioids to include other substances, and updates surveillance and reporting language. It also amends controlled substances law to permit pharmacies to deliver certain schedule III–V drugs to practitioners for administration under expanded conditions, and makes technical and statutory updates to workforce, treatment, and peer-support program authorities. The bill changes program authorizations and funding ceilings across the Public Health Service Act and related statutes, inserts new program authorities and reporting deadlines, expands allowable evidence‑based activities (including wastewater surveillance subject to privacy law), updates professional curricular references, and adds agencies to task force membership. It primarily affects HHS/CDC administration, states/territories/tribes that receive grants, providers (including peer specialists and treatment facilities), and patients with substance use disorders.
Official title: To reauthorize certain programs that provide for opioid use disorder prevention, treatment, and recovery, and for other purposes.
Introduced March 31, 2025 by Brett Guthrie · Last progress December 1, 2025